This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Lysozyme is an enzyme indicated in the treatment of gastrointestinal disorders in infants, as well as Herpes zoster and Herpes simplex.
- Generic Name
- Lysozyme
- DrugBank Accession Number
- DB13260
- Background
Not Available
- Type
- Biotech
- Groups
- Experimental, Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- External IDs
- E-1105
- INS NO.1105
- INS-1105
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in treatment of Gastrointestinal symptoms •••••••••••• •••••• •••••• Adjunct therapy in treatment of Herpes simplex •••••••••••• •••••• Adjunct therapy in treatment of Herpes zoster •••••••••••• •••••• Used in combination for symptomatic treatment of Mouth ulcers Combination Product in combination with: Pyridoxine (DB00165) •••••••••••• ••••••• Used in combination for symptomatic treatment of Orofacial pain Combination Product in combination with: Pyridoxine (DB00165) •••••••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Lysozyme chloride 4YRW73H69V 9066-59-5 Not applicable - International/Other Brands
- Delvozyme
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image E-zyme Syrup Syrup Oral AV MANUFACTURING SDN.BHD 2020-09-08 Not applicable Malaysia 
E-zyme Syrup Syrup 25 mg/5ml Oral AV MANUFACTURING SDN.BHD 2016-12-22 2019-01-09 Malaysia E-zyme troche Tablet, orally disintegrating 200 mg Oral AV MANUFACTURING SDN.BHD 2016-12-22 2019-01-09 Malaysia E-zyme Troche Tablet, orally disintegrating Oral AV MANUFACTURING SDN.BHD 2020-09-08 Not applicable Malaysia Leftose 30mg Tablet Tablet, orally disintegrating Oral ULTRAVITE SDN BHD 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image E-zyme B6 Soothing Liquid Lysozyme chloride (20 mg/5ml) + Pyridoxine hydrochloride (10 mg/5ml) Liquid Oral AV MANUFACTURING SDN.BHD 2020-09-08 Not applicable Malaysia E-zyme B6 Troche Lysozyme chloride (80 mg) + Pyridoxine hydrochloride (40 mg) Tablet, orally disintegrating Oral AV MANUFACTURING SDN.BHD 2020-09-08 Not applicable Malaysia Lyso-B Lozenges Lysozyme chloride (80 mg) + Pyridoxine hydrochloride (40 mg) Lozenge Oral Advance Pharma Sdn Bhd 2020-09-08 Not applicable Malaysia Lyso-B Oral Liquid Lysozyme chloride (20 mg/5ml) + Pyridoxine hydrochloride (10 mg/5ml) Liquid Oral Advance Pharma Sdn Bhd 2020-09-08 Not applicable Malaysia LYSOBACT 20 MG/10 MG PASTİL, 30 ADET Lysozyme chloride (20 mg) + Pyridoxine hydrochloride (10 mg) Lozenge Oral ENFARMA İLAÇ SAN. VE TİC. LTD. ŞTİ. 2020-08-14 Not applicable Turkey 
Categories
- ATC Codes
- J05AX02 — Lysozyme
- J05AX — Other antivirals
- J05A — DIRECT ACTING ANTIVIRALS
- J05 — ANTIVIRALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 968JKA7T33
- CAS number
- 12650-88-3
References
- General References
- AIFA Product Information: Lisozima Spa (lysozyme hydrochloride) oral tablets [Link]
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Asthma / Chronic Obstructive Pulmonary Disease (COPD) 1 4 Completed Treatment Chronic Obstructive Pulmonary Disease (COPD) 1 3 Completed Supportive Care Dry Mouth 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, orally disintegrating Oral Syrup Oral 25 mg/5ml Tablet, orally disintegrating Oral 200 mg Tablet Oral Tablet, orally disintegrating Oral Syrup Oral Tablet Oral 30 mg Tablet Oral 10 MG Tablet Oral 100 MG Tablet Oral 2 MG Tablet Oral 250 MG Tablet Oral 500 MG Liquid Oral Lozenge Oral Tablet Oral 90 mg Syrup Oral 5 mg/ml Capsule - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at June 23, 2017 20:38 / Updated at June 05, 2021 09:13